We partner with companies and teams offering solutions to a broad range of national health security threats. DRIVe partnering approaches vary depending on the project. DRIVe has two main solicitations, our EZ-BAA for awards under $749K and our BAA Special Instructions for larger projects.

For additional details about the COVID-19 response please visit the CDC website


DRIVe EZ-BAA (BAA-20-100-SOL-0002)


Pursuant to FAR 35.016(c), the official posting of the broad agency announcement is available on beta.sam.gov and can be found here: BAA-20-100-SOL-0002. The announcement as it is posted on beta.sam.gov serves as the official Governmentwide point of entry (GPE). The content below is information directly from the GPE and is provided here for ease of reference only. In the event of any conflict or inconsistency between information on the GPE and the below information, the information found on the GPE shall control.


AOI’s Currently Accepting Submissions: :

Unless otherwise noted below, open AOI’s are accepting submissions throughout the EZ-BAA open period which ends 03 February 2023, 1700 HRS ET. BARDA reserves the right to revise the status of submission periods for any of the AOI’s or the EZ-BAA itself. Any change to open periods for submissions will be posted in the form of an amendment / special instruction to the EZ-BAA.




AOI’s NOT Currently Accepting Submissions:



BARDA DRIVe EZ-BAA Document – Originally Posted February 3rd, 2020 - This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) in the Office of Biomedical Advanced Research and Development Authority (BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal Acquisition Regulation (FAR). Abstract submissions selected for award are considered to be the result of full and open competition and in full compliance with 41 U.S.C. § 3301.




Amendments & Special Instructions to the DRIVe EZ-BAA


In addition to reading the full EZ-BAA Document carefully which is found above (DRIVE EZ-BAA.pdf), please read each of the following amendments / special instruction documents and corresponding descriptions to understand how specific guidelines for each of the research areas.



Special Instructions #1 - 2/3/2020 - Please see Special Instructions 001 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of its EZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV.





Special Instructions #2 - 2/15/2020 - Please see Special Instructions 002 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is adding a new topic under its temporary AOI #4: 2019-nCoV as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #3 - 3/9/2020 - Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #4 - 3/18/2020 - Please see Special Instructions 004 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 004, BARDA is closing topic #4.2 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #5 - 4/2/2020 - Please see Special Instructions 005 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 005, BARDA is closing topic #4.1-A and revising topic #4.1-C under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #6 - 4/27/2020 - Please see Special Instructions 006 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 006, BARDA is adding topic #4.1-D under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #7 - 5/12/2020 - Please see Special Instructions 007 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 007, BARDA is closing topics #4.1-B and #4.1-C under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #008 / Amendment #1 - 6/4/2020 - Amendment 001 to the EZ-BAA is now included as an attachment. Amendment 001 revises Section C of the EZ-BAA.

Please also see Special Instructions 008 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 008, BARDA is revising topic #4.3 immediately, and closing topic #4.4 at 1700 HRS ET on 05 June 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #9 - 6/29/2020 - Please see Special Instructions 009 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 009, BARDA is revising topics #4.1-D and #4.3 immediately, and extending the closing date to 2359 HRS ET on 31 October 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #10 - 7/9/2020 - Please see Special Instructions 010 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 010, BARDA is adding topic #4.1-E under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #11 - 10/1/2020 - Please see Special Instructions 011 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 011, BARDA is now accepting abstract submissions for "Area of Interest #5: ReDIRECT (Repurposing Drugs In Response to Chemical Threats)" as part of its EZ-BAA (BAA-20-100-SOL-0002).



Special Instructions #12 - 10/22/2020 - Please see Special Instructions 012 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 012, BARDA is now accepting abstract submissions for "AOI #1: ENACT (Early Notification to Act, Control and Treat)” and "AOI#2: Infection Severity & Solving Sepsis.” Additionally, “AOI #4.3: Alternative Routes of Administration (AROA) for Vaccines” is now “AOI #6: Beyond the Needle".





How to Apply & What to Expect


EZ BAA-20-100-SOL-0002

  • Awards under $750K
  • Emerging Disruptive Ideas
  • Simplified Abstract
  • 30-120 Day Review Target
  1. Review the solicitation on beta.SAM.gov.*
  2. Request an account on the EZ BAA Portal.
  3. Once your account is active, complete the online abstract via the Portal.
  4. BARDA personnel will review your abstract as described in the solicitation.

*Award amounts may differ depending on award structure and/or availability of funding



Straightforward & Transparent Review Proces




  • Streamlined broad agency announcement (“BAA”)
  • Simplified application process
  • Projects under $750,000
  • Cost-share element

DRIVe (Division of Research, Innovation, and Ventures) was established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services (HHS).